Literature DB >> 8392541

Glycoside antibiotics alone and combined with tetracyclines for prophylaxis of experimental cryptosporidiosis in neonatal BALB/c mice.

R Fayer1, W Ellis.   

Abstract

Glycoside antibiotics including the macrolide antibiotics azithromycin, clarithromycin, and erythromycin and the aminoglycoside paromomycin were administered alone or combined with doxycycline, minocycline, or tetracycline to neonatal BALB/c mice experimentally infected with Cryptosporidium parvum. Glycosides at 100 or 200 mg/kg of body weight and tetracyclines at 50 mg/kg of body weight were dissolved in dimethylsulfoxide (DMSO), which was then diluted with phosphate-buffered saline (PBS) and given orally by gavage. Drugs were administered at 0, 24, 48, and 72 hr postinfection (PI) for prophylaxis. Histologic sections of ileum, cecum, and colon from tissues fixed at 96 hr PI were examined microscopically to determine the number of developing parasites and assign a quantitative score based on infectivity. All groups that received glycosides had significantly (P < 0.01) lower scores than controls that received only DMSO/PBS. A range in efficacy was apparent. None or extremely few parasites were found in paromomycin- and azithromycin-treated groups, whereas few to moderate numbers of parasites were found in erythromycin- and clarithromycin-treated groups. The addition of tetracyclines did not consistently result in significantly lower scores.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392541

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  8 in total

1.  Synergistic anticryptosporidial potential of the combination alpha-1-antitrypsin and paromomycin.

Authors:  J R Forney; S Yang; M C Healey
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

2.  Evaluation of curative anticryptosporidial activity of paromomycin in a dexamethasone-treated rat model.

Authors:  R Verdon; J Polianski; C Gaudebout; C Marche; L Garry; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

3.  A newborn mouse Cryptosporidium parvum infection model: its application to the study of therapeutic and prophylactic measures for controlling cryptosporidiosis in ruminants.

Authors:  S Martín-Gómez; Ma Alvarez-Sánchez; Fa Rojo-Vázquez
Journal:  Parasitol Res       Date:  2006-01-31       Impact factor: 2.289

4.  Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide, and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model.

Authors:  B L Blagburn; K L Drain; T M Land; R G Kinard; P H Moore; D S Lindsay; D A Patrick; D W Boykin; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 5.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

6.  Chemoprophylaxis of Cryptosporidium parvum infection with paromomycin in kids and immunological study.

Authors:  R Mancassola; J M Reperant; M Naciri; C Chartier
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

7.  Evaluation of high-dose regimen of paromomycin against cryptosporidiosis in the dexamethasone-treated rat model.

Authors:  R Verdon; J Polianski; C Gaudebout; C Marche; L Garry; C Carbon; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

8.  Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin.

Authors:  S Tzipori; W Rand; J Griffiths; G Widmer; J Crabb
Journal:  Clin Diagn Lab Immunol       Date:  1994-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.